PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26041888-0	2015	Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action.	25-methoxylprotopanaxadiol	33-56	MDM2 proto-oncogene	Homo sapiens	85-89	
26041888-3	2015	We have recently identified a novel ginsenoside, 25-OCH3-PPD (GS25), one of the most active anticancer ginsenosides discovered thus far, and have demonstrated its MDM2 inhibition and anticancer activity in various human cancer models, including prostate cancer.	25-methoxylprotopanaxadiol	62-66	MDM2 proto-oncogene	Homo sapiens	163-167	
26041888-6	2015	After GS25 was successfully encapsulated into PEG-PLGA nanoparticles (GS25NP) and its physicochemical properties were characterized, the efficiency of MDM2 targeting, anticancer efficacy, pharmacokinetics, and safety were evaluated in in vitro and in vivo models of human prostate cancer.	25-methoxylprotopanaxadiol	6-10	MDM2 proto-oncogene	Homo sapiens	151-155	
22911819-0	2012	Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.	25-methoxylprotopanaxadiol	16-39	MDM2 proto-oncogene	Homo sapiens	109-113	
22911819-5	2012	We further demonstrated that, in a dose- and time-dependent manner, 25-OCH(3)-PPD inhibited MDM2 expression at both transcriptional and post-translational levels in human breast cancer cells with various p53 statuses (wild type and mutant).	25-methoxylprotopanaxadiol	68-81	MDM2 proto-oncogene	Homo sapiens	92-96